A Melbourne-based life insurance company has been tapped to undertake a pilot program for a mental-health technology company’s latest corporate health program.
AIA Australia (AIAA) and ASX-listed Medibio inked an exclusive agreement for AIAA to access ilumen over a six-month period, allowing the insurer’s Australia and New Zealand employees to benefit from a two-part system for checking and monitoring symptoms of depression, anxiety, and stress.
The system combines Medibio’s key biometric data and a subjective assessment to provide users a “wellness snapshot” that they can track and make improvements to over time.
“AIAA provides a great opportunity for ilumen,” said Jennifer Solitario, senior vice president of corporate health at Medibio. “Our objective is to bring our unique mental health technology to as many people as possible. AIAA offers us an opportunity to partner with a leading organisation with a genuine interest in helping to support mental health for its people.”
“AIAA recognises the crucial role mental health plays in an individual’s overall health,” said Damien Mu, AIA Australia and New Zealand CEO. “We will continue to explore ways of improving the support that we provide to our staff, customers and partners as we strive to help people live healthier, longer, better lives.”
